A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
A phase 2 trial of Ipatasertib, Cobimetinib, Trastuzumab emtansine in ovarian cancer, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors is a phase 2 interventional study registered as NCT04931342 by Hoffmann-La Roche, with 176 participants enrolled, started 2021-10-07 and due to reach its primary completion in 2028-02-28. Interventions recorded: Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab, Bevacizumab. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Shares Ipatasertib, Roche / Genentech.
- TrialA Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Shares Atezolizumab, Roche / Genentech, Bevacizumab.
- TrialA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
Shares Atezolizumab, Roche / Genentech, Bevacizumab.
- TrialA Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell
Shares Atezolizumab, Roche / Genentech, Bevacizumab.
- TrialA Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialTumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Shares Ipatasertib, Trastuzumab emtansine, Atezolizumab.
- TrialA Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Shares Cobimetinib, Atezolizumab, Roche / Genentech.
- TrialOregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer.